1 Eklof Bo, Rutherford RB, Bergan JJ, Carpentier PH, Cloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: Consensus statement. J
Vasc Surg 2004; 40: 1248-52
2 Lurie F., Passman M., Meisner M., Dalsing M., Masuda E., Welch H., et al. CEAP classification system and reporting standard, revision 2020. J. Vasc. Surg: Venous and Lym
3 Santler B., Gӧrge T. Chronic venous insufficiency-a review of pathophysiology, diagnosis, and treatment. J. Germ. Soc. Derm. (JDDG) 2017:538-556.
4 Labropoulos N. Hemodynamic changes according to the CEAP classification. Phlebology 2003; 40: 130-36.
5 Labropoulos N, Patel PJ, Tiongson JE, Pryor L, Leon LR, Tassiopoulos AK, et al. Patterns of venous reflux and obstruction in patients with skin damage due to chronic venous
disease. Vasc Endovasc Surg 2007; 41:33-40.
6 Chiesa R, Marone EM, Limoni C, Volonte M, Schaefer E, Petrini O, et al. Demographic factors and their relationship with the presence of CVI singns in Italy: the 24-cities
cohort study. Eur J Vasc Endovasc Surg 2005; 30: 674-80.
7 Canonico S, Gallo C, Paolisso G, Pacifico F, Varricchio M, Regno F, et al. Prevalence of varicose veins in an Italian elderly population, Angiology 1998; 49: 129-35.
8 Gundersen J, Hauge M. Hereditary factors in venous insufficiency. Angiology 1969; 20: 346-55.
9 Hobson J. Venous insufficiency at work. Angiology 1997; 48: 577-82.
10 Lionis C, Erevnidou K, Antonakis N, Argyriadou S, Vlachonikolis I, Katsamouris A, et al. Chronic venous insufficiency. A common health problem in general practice in Greece.
Int Angiology 2002; 86-92.
11 Scott TE, La Morte WW, Gorin DR, Menzoian J. Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg 1995; 22: 622-28.
12 Jawiem A. The influence of environmental factors in chronic venous insufficiency. Angiology 2003; 54: S19-S31.
13 Bergan JJ, Schmid-Shonbein GN, Coleridge Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease, N Eng J Med 2006; 355: 488-98.
14 Burnand KG. The physiology and hemodynamics of chronic venous insufficiency of the lower limb. In Gloviczki P, Yao JS, eds Handbook of Venous Disorders. 2nd ed. New York, NY: Arnold; 2001: 49-57.
15 Delis KT, Husmann M, Kalodiki E, Wolfe JH, Nicolaides AN. In situ hemodynamics of perforating veins in chronic venous insufficiency. J Vasc Surg 2001; 33: 773-82.
16 Labropoulos N, Tiongson J, Pryor L, Tassiopoulos AK, Kang SS, Mansour MA, et al. Definition of venous reflux in the lower extremity veins. J Vasc Surg 2003; 38: 793-98.
17 Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J
1982; 285: 1071-72.
18 Berk B.C., Abe JI, Min W, Surapisitchat J., Yan C. Endothelial Atheroprotective and Anti-inflammatory Mechanisms. An. N.Y. Acad. Sci. 2001; 947: 93-111.
19 Passerini AG, Milsted A, Rittgers SE. Shear stress magnitude and directionality modulate growth factor gene expression in preconditioned vascular endothelial cells. Journal of vascular surgery. 2003 Jan 1;37(1):182-90.
20 Zhao Y, Chien S, Weinbaum S. Dynamic contact forces on leukocyte microvilli and their penetration of the endothelial glycocalyx. Biophysical journal. 2001 Mar 1;80(3):1124-40.
21 Colon JAB, Granados-Romero JI, Barrera-Mera B, Banegas-Ruiz R, Vargas-Morales JJ, Barera-Calva E., et al. Chronic venous insufficiency: A review. Int. J. Res. Med. Sci. 2021; 9 (6): 1808-1815.
22 Norgauer J, Hildenbrand T, Idzko M, Panther E., Bandemir E, Hartmann M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD 147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147: 1180-86.
23 Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998; 111: 822-27.
24 Mwaura B, Mahendvan B, Hynes N, Defreitas D, Avalos G, Adegbola T, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix
metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31: 306-10.
25 Junger M, Hahn U, Bort S, Klyscz T, Hahn M, Rassner G. Significance of cutaneous microangiopathy for the pathogenesis of dermatitis in venous congestion due to chronic venous insufficiency. Wien Med Wochenschr 1994; 144:206-10.
26 Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 1996; 271: H2520-H2528.
27 Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg 1998; 28: 535-40.
28 Idem. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction – a pilot study. Eur J Vasc Endovasc Surg
1999; 18: 334-38.
29 Pappas PJ, You R, Rameshwar P, Gorti R, David O, Phillips CK, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-b1 gene expression and protein production. J Vasc Surg 1999; 30:1129-45.
30 Kanta J., Zavadakora A. Role of fibronectin in chronic venous disease: A review Vasc. Med. 2020;1-10.
31 Bugnamini AA, Matuska J. Sulodexide for the symptoms and sings of chronic venous disease. A systematic review and meta-analysis. Adv. Ther. 2020; 1013-33.
32 Wenk J, Foitzik A, Achterberg V, Sabiwalsky A, Dissemond J, Meewes C, et al. Selective pick-up of increased iron by deferoxamine-coupled cellulose abrogates the iron-driven induction of matrix-degrading metalloproteinase-1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing consept. J Invest Dermatol 2001;116: 833-39.
33 Zamboni P, Tognazzo S, Izzo M, Gemmati D. Hemochromatosis C282Y gene mutation increases the risk of venous leg-ulceration. J Vasc Surg 2005; 42: 309-14
34 Ambrosch A, Lobmann R, Pott A, Preibler J. Interleukin – 6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer
formation. Int Wound J 2008; 5: 99-106.
35 Gunawardena T., Gunawansa N. Incompetent perforator veins; To treat or not to treat. J Vasc Surg 2019; 5(1): 1-4. 36 Labropoulos N. Current views on the management of incompetent perforator veins. Ann Phlebology 2020; 18(1): 1-3.
37 Bradbury AW. Epidemiology and aetiology of C4-6 disease. Phlebology 2010; 25 Suppl 1:2-8.
38 Idem. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction – a pilot study. Eur J Vasc Endovasc Surg 1999; 18: 334-38.
39 Shai A, Halevy S. Direct triggers for ulceration in patients with venous insufficiency. International journal of dermatology. 2005 Dec;44(12):1006-9.
40 Harding KG, Moore K, Phillips TJ. Chronicity and fibroblast senescence-implications for treatment. Int Wound J 2005; 2: 364-68.
41 Stojadinovic O, Pastar I, Vukelic S, Mahoney G, Brennan D, Kryzanowska A, et al. Deregulation of keratinocyte differentiation and activation: a hallmark of venous ulcers. J Cell Mol Med 2008; 12: 2675-90.